Previous close | 31.49 |
Open | 31.32 |
Bid | 31.18 x 50000 |
Ask | 32.12 x 50000 |
Day's range | 31.32 - 31.32 |
52-week range | 22.35 - 34.48 |
Volume | |
Avg. volume | 116 |
Market cap | 61.007B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 50.52 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.36 (1.15%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), the Anglo-Swedish drugmaker said on Monday. The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible financial incentives from the Singapore government.
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt